TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Brendan Smith maintains a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $59 to $65.
August 07, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Brendan Smith maintains a Buy rating on Halozyme Therapeutics and raises the price target from $59 to $65.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100